HCV Genotype 1 Infection: IFN-Free Treatment with Direct-Acting Antivirals Available in 2015

被引：0
作者：
Bourlière M. [1 ]
Asselah T. [2 ]
机构：
[1] Department of Hepato-Gastroenterology, Hospital Saint Joseph, Marseilles
[2] Hepatology Department, AP-HP, University Paris Diderot 7 and INSERM U773, CRB3, Beaujon Hospital, 100 Bd du Général Leclerc, Clichy
来源：
Current Hepatology Reports | 2015年 / 14卷 / 4期
关键词：
Daclatasvir; Dasabuvir; Elbasvir; Grazoprevir; Ledipasvir; Ombitasvir; Paritaprevir; Sofosbuvir;
D O I：
10.1007/s11901-015-0282-6
中图分类号：
学科分类号：
摘要：
There is a revolution in the treatment of chronic hepatitis C with several oral regimen with direct-acting antivirals (DAAs) being developed, increasing sustained virological success rates and shortened treatment duration. In 2014–2015, combinations of DDAs with additive potency that lack cross-resistance and with a good safety profile may provide new regimens to make hepatitis C virus (HCV) the first chronic viral infection eradicated worldwide. The aim of this review is to summarize results from approved or available complete phase III clinical trials obtained with oral DAAs combination, regimen available in 2015 in several countries for genotype 1 patients. © 2015, Springer Science+Business Media New York.
引用
收藏
页码：260 / 266
页数：6
相关论文
共 32 条
  • [1] Marcellin P., Asselah T., Boyer N., Fibrosis and disease progression in hepatitis C, Hepatology, 36, pp. S47-S56, (2002)
  • [2] Choo Q.L., Kuo G., Weiner A.J., Et al., Isolation of a cDNA clone derived from a blood-borne non-a, non-B viral hepatitis genome, Science, 244, 4902, pp. 359-362, (1989)
  • [3] Asselah T., Marcellin P., Direct acting Antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow, Liver Int, 32, pp. 88-102, (2012)
  • [4] Kim J.L., Morgenstern K.A., Lin C., Et al., Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide, Cell, 87, 2, pp. 343-355, (1996)
  • [5] Yao N., Hesson T., Cable M., Et al., Structure of the hepatitis C virus RNA helicase domain, Nat Struct Biol, 4, 6, pp. 463-467, (1997)
  • [6] Estrabaud E., Vidaud M., Marcellin P., Et al., Genomics and HCV infection: progression of fibrosis and treatment response, J Hepatol, 57, 5, pp. 1110-1125, (2012)
  • [7] Schinazi R., Halfon P., Marcellin P., Et al., HCV direct-acting antiviral agents: the best interferon-free combinations, Liver Int, 34, pp. 69-78, (2014)
  • [8] Halfon P., Locarnini S., Hepatitis C virus resistance to protease inhibitors, J Hepatol, 55, 1, pp. 192-206, (2011)
  • [9] Pawlotsky J.M., New hepatitis C therapies, Semin Liver Dis, 34, 1, pp. 7-8, (2014)
  • [10] Martinot-Peignoux M., Stern C., Maylin S., Et al., Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving Pegylated interferon and ribavirin, Hepatology, 51, 4, pp. 1122-1126, (2010)
1234